Only 3 Months of Aspirin and Plavix after a Drug Eluting Stent?

Nice article in Cardiology News: http://tinyurl.com/7xxmga3

Major Finding: Patients assigned to 3 months of dual antiplatelet therapy following implantation of a zotarolimus-eluting stent had a 1-year combined adverse event rate of 4.7%, identical to that in recipients of other drug-eluting stents plus the standard 12 months of dual antiplatelet therapy.

Data Source: An open-label, randomized trial including 2,117 patients who received a zotarolimus-eluting Endeavor stent and 3 months of dual antiplatelet therapy, or a different drug-eluting stent and the standard 12 months of dual antiplatelet therapy.

Disclosures: The study was sponsored by the South Korean Ministry of Health and Welfare, the Cardiovascular Research Center of Seoul, and Medtronic.